Dina Titus sold Bristol-Myers Squibb Company (NYSE: BMY)
Dina Titus (D-NV), a U.S. Representative, has disclosed 1 trade in Bristol-Myers Squibb Company (BMY) since 2015, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Dina Titus sold $15,001 - $50,000 of Bristol-Myers Squibb Company (NYSE: BMY) on November 24, 2015. Since that trade, BMY is up +33.06% against the S&P 500 up +314.70%, an outperformance of -281.64%.
Data updated
Dina Titus's BMY trades vs the price
BMY is up +33.06% since Dina Titus sold on November 24, 2015, versus +314.70% for the S&P 500.
Performance since this trade
All Dina Titus BMY trades
Dina Titus & BMY trading FAQ
Is it legal for Dina Titus to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Dina Titus sell BMY?
Dina Titus disclosed a sale of $15,001 - $50,000 of Bristol-Myers Squibb Company (BMY) on November 24, 2015, according to public STOCK Act filings.
How has BMY performed since Dina Titus's trade?
Since Dina Titus sold BMY on November 24, 2015, the stock is up +33.06%, versus +314.70% for the S&P 500 over the same period, an outperformance of -281.64%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
Dina Titus's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyDina Titus's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.